KSPHF.US Kissei Pharmaceutical Co. Ltd
- Market cap
- USD 1.02B
- P/E
- 14.4x
- P/B
- 0.72x
- ROE
- 4.5%
- Dividend yield
- 3.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is KSPHF.US undervalued?
Graham numberKSPHF.US trades 32.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kissei Pharmaceutical Co. Ltd fundamental analysis
No fundamental analysis for Kissei Pharmaceutical Co. Ltd yet.
Kissei Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kissei Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Da…
Full company profileKissei Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kissei Pharmaceutical Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 644M | 696M | 653M | 586M | 69.0B | 65.4B | 67.5B | 75.6B | 88.3B | 98.0B | 91.2B |
| Gross Profit | 412M | 445M | 403M | 314M | 280M | 238M | 224M | 37.3B | 44.1B | 46.1B | 43.5B |
| Operating Income | 76.2M | 93.0M | 56.1M | 17.2M | 1.51B | -1.40B | -1.13B | 4.02B | 5.77B | -2.94B | 3.39B |
| EBITDA | 12.5B | 14.2B | 9.75B | 7.22B | 4.65B | 2.33B | 2.97B | 18.7B | 20.2B | 1.70B | 8.11B |
| Net Income | 69.3M | 85.1M | 49.5M | 26.1M | 5.29B | 12.9B | 10.5B | 11.2B | 12.0B | 13.9B | 10.3B |
| EPS | 1.42 | 1.77 | 1.06 | 0.56 | 113 | 280 | 228 | 247 | 274 | 334 | 241 |
| Balance Sheet | |||||||||||
| Total Assets | 1.68B | 1.98B | 1.93B | 2.15B | 2.43B | 1.96B | 1.66B | 261B | 244B | 277B | 268B |
| Total Liabilities | 260M | 329M | 281M | 360M | 443M | 297M | 199M | 39.8B | 33.9B | 43.8B | 37.4B |
| Shareholders' Equity | 1.41B | 1.65B | 1.65B | 1.78B | 219B | 201B | 194B | 220B | 209B | 232B | 229B |
| Cash & Short-term Investments | 432M | 448M | 446M | 553M | 44.5B | 53.2B | 49.6B | 45.9B | 48.7B | 54.8B | 53.9B |
| Total Debt | 32.1M | 37.0M | 36.8M | 1.76B | 1.74B | 1.64B | 1.49B | 1.34B | 1.28B | 1.26B | 1.26B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 57.8M | 83.2M | 57.3M | 129M | -23.0M | 1.53B | -6.68B | -1.68B | 6.52B | -1.49B | - |
| Capital Expenditure | 22.8M | 23.7M | 18.2M | 16.7M | 93.3M | 47.0M | 54.5M | 1.83B | 5.03B | 4.91B | 2.49B |
| Free Cash Flow | 35.0M | 59.4M | 39.1M | 112M | -116M | -34.4M | -105M | -3.51B | 1.49B | -6.41B | - |
| Ratios | |||||||||||
| ROE | 4.9% | 5.1% | 3.0% | 1.5% | 2.4% | 6.4% | 5.4% | 5.1% | 5.7% | 6.0% | 4.5% |
| ROA | 4.1% | 4.3% | 2.6% | 1.2% | 217.2% | 660.6% | 632.3% | 4.3% | 4.9% | 5.0% | 3.9% |
| Net Profit Margin | 10.8% | 12.2% | 7.6% | 4.5% | 7.7% | 19.8% | 15.6% | 14.8% | 13.5% | 14.1% | 11.3% |
| Debt to Equity | 0.02x | 0.02x | 0.02x | 0.99x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kissei Pharmaceutical Co. Ltd dividends
- Dividend yield
- 3.32%
- Forward dividend
- 0.81 USD
- Payout ratio
- 35.1%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 4.87B | 117 | 35.1% |
| 2025 | JPY 3.80B | 87 | 31.8% |
| 2024 | JPY 3.72B | 82 | 33.4% |
| 2023 | JPY 3.14B | 68 | 29.8% |
| 2022 | USD 2.54B | 55 | 19.6% |
| 2021 | USD 2.48B | 53 | 46.8% |
| 2020 | USD 2.38B | 51 | 9,128.5% |
| 2019 | USD 2.29B | 49 | 4,622.5% |
| 2018 | JPY 21.3M | 0.44 | 25.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 11:10 on Mar 26, 1996.
Who owns Kissei Pharmaceutical Co. Ltd
- Insiders 21.67%
- Institutions 28.20%
- Public & others 50.13%
- Shares outstanding 41.7M
- Free float 35.0M
Kissei Pharmaceutical Co. Ltd company profile
- Company name
- Kissei Pharmaceutical Co. Ltd
- Ticker
- KSPHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,786
- Fiscal year end
- March
- Address
- 19-48, Yoshino, Matsumoto, Japan, 399-8710
- Phone
- 81 2 6325 9081
- Website
- kissei.co.jp
About Kissei Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, that is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0914 that is in Phase I clinical trial to treat Graves' disease; KPS-0373, that is in Phase III clinical trial to treat Spinocerebellar degeneration; KSP- 0576 that is in Phase I clinical trial to treat interstitial cystitis and bladder pain syndrome; and KSP-0930, which is in Phase I clinical trial to treat Narcolepsy. It also develops Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; purchases and sells related materials; and offers system development and information processing, facility and equipment management, and information gathering and development support services. Further, it engages in information equipment rentals; insurance agency business; manufactures and sells noodles; construction contracting; and computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.
Kissei Pharmaceutical Co. Ltd management
8- Mr. Mutsuo KanzawaChairman & CEO · born 1949
- Mr. Keiji MiyazawaPresident, COO & Director · born 1967
- Mr. Takahide KitaharaGM of Financial Management Department, Executive MD & Executive Director · born 1962
- Mr. Tetsu TakayamaExecutive VP, CHRO & Director · born 1961
- Mr. Yoshio FurihataSenior Advisor & Director · born 1962
- Hiroshi NoakeGM of Pharmaceutical Sales Headquarters, MD & Director · born 1964
- Mr. Takayuki KomamuraCorporate Officer, Senior Director of Corporate Finance & Management Department and Director · born 1966
- Ms. Nobuko YanagiSenior Director of General Administration Dept & Sustainability Management and Director · born 1968